Gain Therapeutics Reports 12-Month Phase 1b Data Showing Motor Score Stabilization in Parkinson's
GANX is trading near its 52-week low of $1.53 (15% above the low).
Summary
Gain Therapeutics announced 12-month Phase 1b open-label extension data showing stabilization of motor symptoms in Parkinson's patients treated with rexaceract, with plans to initiate a Phase 2 trial in Q1 2027.
Updates
· GlobeNewswire — Poster presented at MDS Congress; 12 of 13 evaluable patients completed 12-month dosing by Aug 31, 2026, with one to complete in November 2026.
Key Events · Product Development and Regulatory · GANX
-
12-Month Motor Score Stabilization
MDS-UPDRS motor scores remained stable over 360 days of dosing in 12 evaluable patients, with no clinically meaningful progression on Parts II and III — a threshold generally accepted as ~6 points per year in early PD.
-
Phase 2 Initiation Planned for Q1 2027
Company expects to submit a new Phase 2 study protocol to the FDA in the coming weeks and initiate the Phase 2 clinical trial of rexaceract in Parkinson's disease in the first quarter of 2027.
-
Biomarker Data Supports Mechanism
Participants with high baseline CSF GluSph levels showed a large decrease toward healthy levels after 90 days of treatment, suggesting increased GCase activity in the brain — consistent with rexaceract's proposed mechanism.
-
Favorable Long-Term Safety Profile
No new safety signals observed over 12 months; lower incidence of treatment-emergent adverse events in the nine-month extension (Part 2) compared with the initial three-month period (Part 1).
Analysis · GANX · Life Sciences
The 12-month open-label extension data for rexaceract shows MDS-UPDRS motor scores remained stable over 360 days of dosing, with no clinically meaningful progression in 12 evaluable patients. This is the first long-term efficacy signal for the company's lead asset and supports its disease-modifying hypothesis in Parkinson's disease. The company also confirmed plans to submit a Phase 2 protocol to the FDA in the coming weeks and initiate the trial in Q1 2027, providing a concrete near-term development milestone. Against a backdrop of a going-concern warning and only $13.1M in cash as of Q2 2026, positive clinical data is critical for attracting partnership or financing interest to fund the next phase.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GANX was trading at $1.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $75.5M. The 52-week trading range was $1.53 to $4.34. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.